Viracta Therapeutics Statistics
Share Statistics
Viracta Therapeutics has 39.74M shares outstanding. The number of shares has increased by 1.2% in one year.
| Shares Outstanding | 39.74M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.83% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 28.01M |
| Failed to Deliver (FTD) Shares | 10.31K |
| FTD / Avg. Volume | 0.41% |
Short Selling Information
The latest short interest is 2.69M, so 6.77% of the outstanding shares have been sold short.
| Short Interest | 2.69M |
| Short % of Shares Out | 6.77% |
| Short % of Float | 9.61% |
| Short Ratio (days to cover) | 1.85 |
Valuation Ratios
The PE ratio is -0.43 and the forward PE ratio is -0.29.
| PE Ratio | -0.43 |
| Forward PE | -0.29 |
| PS Ratio | 0 |
| Forward PS | 0.5 |
| PB Ratio | 1.2 |
| P/FCF Ratio | -0.55 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Viracta Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.43, with a Debt / Equity ratio of 1.38.
| Current Ratio | 1.43 |
| Quick Ratio | 1.44 |
| Debt / Equity | 1.38 |
| Total Debt / Capitalization | 57.98 |
| Cash Flow / Debt | -1.58 |
| Interest Coverage | -13.69 |
Financial Efficiency
Return on equity (ROE) is -2.79% and return on capital (ROIC) is -115.54%.
| Return on Equity (ROE) | -2.79% |
| Return on Assets (ROA) | -0.9% |
| Return on Capital (ROIC) | -115.54% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.28M |
| Employee Count | 40 |
| Asset Turnover | 0 |
| Inventory Turnover | -3.64 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -63.33% in the last 52 weeks. The beta is 0.3, so Viracta Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.3 |
| 52-Week Price Change | -63.33% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.47 |
| Relative Strength Index (RSI) | 57.81 |
| Average Volume (20 Days) | 2.49M |
Income Statement
| Revenue | n/a |
| Gross Profit | -492.00K |
| Operating Income | -50.69M |
| Net Income | -51.06M |
| EBITDA | -46.86M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.32 |
Balance Sheet
The company has 12.32M in cash and 25.56M in debt, giving a net cash position of -13.24M.
| Cash & Cash Equivalents | 12.32M |
| Total Debt | 25.56M |
| Net Cash | -13.24M |
| Retained Earnings | -265.93M |
| Total Assets | 21.96M |
| Working Capital | -6.77M |
Cash Flow
In the last 12 months, operating cash flow was -39.89M and capital expenditures -138.00K, giving a free cash flow of -40.03M.
| Operating Cash Flow | -39.89M |
| Capital Expenditures | -138.00K |
| Free Cash Flow | -40.03M |
| FCF Per Share | -1.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VIRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -600% |
| FCF Yield | -457.81% |
Analyst Forecast
The average price target for VIRX is $3, which is 1263.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 1263.6% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Feb 25, 2021. It was a backward split with a ratio of 57:200.
| Last Split Date | Feb 25, 2021 |
| Split Type | backward |
| Split Ratio | 57:200 |
Scores
| Altman Z-Score | -24.99 |
| Piotroski F-Score | 2 |